Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

cromet-inc.com" target="_new">(http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual result
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... announced that the U.S. Food and Drug Administration ... treatment of adult patients with glioblastoma multiforme (GBM) ...  The portable, wearable device delivers an anti-mitotic, anti-cancer ... The NovoTTF is a novel, first-in-class treatment option ...
... 2011 StelKast is proud to announce the ... Acetabular Liners. EXp™, a blend of antioxidant and ... consulting support of Steven Kurtz, Ph.D. and Exponent, ... clearance for large diameter cobalt-chrome femoral heads and ...
Cached Medicine Technology:FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 2FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 3FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 4A Better Acetabular Solution from StelKast ... Naturally 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... include a wealth of information for specific translation services within the medical and ... an incredible track record of successful work. , ITC Global Translations specializes in ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award ... September 1. , “Alive Inside” shadows a social worker who advocates for the use ... a documentary about bringing music to residents in health care centers who may have ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... high quality, patient-oriented dental care. From the moment a patient arrives at the ... and Steven Tuckman will work with each and every patient to create a complete ...
Breaking Medicine News(10 mins):Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2
... ... SecureWorks®, Inc., a leading global provider of information security services ... at its healthcare clients doubled in the fourth quarter of 2009. ... per day in the first nine months of 2009 to an ...
... evolution a field that often deals with changes over ... disease in our lifetime? A lot, some scientists say. If ... on evolution in medical entrance and licensing exams, says an ... articles in the January 26 issue of Proceedings of ...
... technique to catch cancer early has taken an important ... NPL,s ,phantoms, will ensure an exciting new screening technique ... signs of cancer. The technique, Optical Coherence Tomography ... the surface of certain materials, notably human tissue. It ...
... Improved delivery of end-of-life care in prison is the ... of Nursing Research that has Penn State researchers working ... Department of Corrections. The project will develop an intervention ... the country. End-of-life care -- an attempt to optimize ...
... 26, 2010 A Universit de Montral research team is ... our brain to stop eating. "Mice deprived of leptin will ... moving around," says Mose Bendayan, a pathology professor at the ... leptin protein extensively. Leptin regulates appetite in mammals and ...
... ... is on a mission to meet Matt Lauer when he is in Vancouver to shoot ... ... fruit bars ( www.elevateme.com ) is on a mission to meet Matt Lauer when he ...
Cached Medicine News:Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 2Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 3Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 4Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 5Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 6Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 7Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:New measurement technique will help in fight against cancer 2Health News:End-of-life care strategies examined in Pennsylvania prisons 2Health News:A gimmick-free weight-loss pill in the works 2Health News:Vancouver Company Must Meet Matt Lauer During Olympics 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
Smooth colibri tip; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Medicine Products: